Rezzayo is the first new echinocandin antifungal approved by the FDA in over 15 years for adults with limited or no alternative options for treating candidemia and invasive candidiasis. It works by inhibiting fungal β-glucan synthase, thereby disrupting cell wall synthesis, and simplifying care with once-weekly intravenous dosing.